Author

M. J. Ellis

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 4 Biochemistry· 1 Microbiology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 5 Organism:human· 4 Assay:bulk RNA-seq· 3 Research Focus:drug response / drug discovery· 3 Assay:proteomics· 3 Research Focus:cell signaling & trafficking· 2 Research Focus:cell type annotation· 2 Research Focus:differential expression· 2

Frequent Co-Authors

A. B. Saltzman· 3 shared A. Malovannaya· 3 shared P. Singh· 3 shared B.-J. Kim· 2 shared D. Chan· 2 shared E. J. Jaehnig· 2 shared M. Anurag· 2 shared M. Rimawi· 2 shared

Activity by Year

2018-2022 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 37 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

3 shared papersCancer Biology

A. B. Saltzman

Mutual co-authors in cluster

Author profile →

6 papers

Recent·Most cited

Kinase Inhibitor Pulldown Assay (KiP) for Clinical Proteomics

A. B. Saltzman, D. Chan, M. V. Holt, J. Wang, E. J. Jaehnig, M. Anurag, P. Singh, A. Malovannaya, B.-J. Kim, M. J. Ellis

The paper introduces a kinase inhibitor pulldown assay (KiP) combined with PRM for clinical proteomics, improving kinase quantification in cancer samples.

bioRxiv · Oct 13, 2022Biochemistry

A Network Approach to Identify Biomarkers of Differential Chemotherapy Response Using Patient-Derived Xenografts of Triple-Negative Breast Cancer

V. Petrosyan, L. E. Dobrolecki, L. Thistlethwaite, A. N. Lewis, C. Sallas, R. Rajaram, J. T. Lei, M. J. Ellis, K. Osborne, M. Rimawi, A. Pavlick, M. Shafaee, H. Dowst, A. B. Saltzman, A. Malovannaya, , M. T. Lewis

This paper identifies biomarkers of differential chemotherapy response in TNBC using a network-based approach and validates them in PDX models and clinical datasets.

bioRxiv · Aug 20, 2021 · PreprintCancer Biology

Phenotypic plasticity of ER+ breast cancer in the bone microenvironment

I. L. Bado, H. Wang, P. Sarkar, J. Liu, W. Wu, W. Zhang, H.-C. Lo, A. Muscallera, M. Janghorban, I.-S. Kim, S. Singh, A. Goldstein, P. Singh, H. Shixia, G. M. Waleed, , X. H. F. Zhang

The paper shows that the bone microenvironment induces endocrine resistance in ER+ breast cancer metastases through epigenomic reprogramming mediated by EZH2.

bioRxiv · Nov 14, 2020 · PreprintCancer Biology

Mismatch repair deficiency predicts response to HER2 blockade in HER2-negative breast cancer

N. B. Punturi, S. Seker, V. Devarakonda, R. Kalra, C.-H. Chen, A. Mazumder, S.-Q. Li, T. Primeau, M. J. Ellis, S. M. Kavuri, S. Haricharan

This study shows that loss of MLH1, a mismatch repair gene, activates HER2 in ER+/HER2- breast cancer, making these cells sensitive to HER2 inhibitors.

bioRxiv · Jun 8, 2020Cancer Biology

Microscaled Proteogenomic Methods for Precision Oncology

S. Satpathy, E. J. Jaehnig, K. Krug, B.-J. Kim, A. B. Saltzman, D. Chan, K. R. Holloway, M. Anurag, C. Huang, P. Singh, A. Gao, N. Namai, Y. Dou, B. Wen, S. Vasaikar, , M. J. Ellis

This study develops microscaled proteogenomic methods for cancer analysis, showing treatment response and resistance mechanisms in ERBB2-positive breast cancers.

bioRxiv · Oct 9, 2019Cancer Biology

A macrophage-based screen identifies antibacterial compounds selective for intracellular Salmonella Typhimurium

M. J. Ellis, C. N. Tsai, J. W. Johnson, S. French, W. Elhenawy, S. Porwollik, H. Andrews-Polymenis, M. McClelland, J. Magolan, B. K. Coombes, E. D. Brown

The paper identifies antibacterial compounds effective against intracellular Salmonella Typhimurium through macrophage-based screens and shows metergoline enhances activity by perturbing the bacterial outer membrane.

bioRxiv · Aug 2, 2018Microbiology